Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

The NSG-hIL6 Mouse As a Novel Murine Patient Derived Xenograft Model of Plasma Cell Dyscrasias for Study of Disease Biology and Therapeutic Development

Zainul Hasanali, Alfred L. Garfall, Martin P. Carroll, Anthony Secreto, Nicolas Skuli, Carly Roman, Leonard Shultz, Neil Sheppard, Edward A. Stadtmauer, David Allman

Blood (2022) 140 (Supplement 1): 9921–9922.

https://doi.org/10.1182/blood-2022-167751

Published: 2022

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

V. S. S. Abhinav Ayyadevara, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll, Christian Hurtz

Blood (2022) 140 (Supplement 1): 3486–3488.

https://doi.org/10.1182/blood-2022-162782

Published: 2022

Journal Articles

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1022–1024.

https://doi.org/10.1182/blood-2022-168036

Published: 2022

Journal Articles

Targeting the Mevalonate Pathway in the Mitochondria-Dependent Chemotherapy Resistance of TP53 Mutant Acute Myeloid Leukemia

Sarah Skuli, A'Ishah Bakayoko, Bryan Manning, Gerald Wertheim, Jimmy Xu, Eva Nee, Lorelai Mesaros, Ryan Hausler, Manuela Lavorato, Eiko Ogiso, Marni Falk, Kara N. Maxwell, Nicolas Skuli, Clementina Mesaros, Martin P. Carroll

Blood (2022) 140 (Supplement 1): 8791–8792.

https://doi.org/10.1182/blood-2022-165660

Published: 2022

Journal Articles

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

Blood (2022) 139 (24): 3546–3557.

https://doi.org/10.1182/blood.2021014520

Published: 2022

Includes: Supplemental data

Journal Articles

FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation

Pamela J. Sung, Simone Sidoli, Simone S. Riedel, Katarzyna Kulej, Hongbo Xie, Bryan Manning, Daniel Tsai, Gerald Wertheim, Benjamin A. Garcia, Sara E. Meyer, Kathrin M. Bernt, Martin P. Carroll

Blood (2021) 138 (Supplement 1): 785.

https://doi.org/10.1182/blood-2021-147313

Published: 2021

Journal Articles

A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia

Marta Galan-Diez, Florence Borot, Abdullah M. Ali, Junfei Zhao, Eva Gil-Iturbe, Xiaochuan Shan, Xi-Ping Huang, Irwin Kurland, Bryan L. Roth, Matthias Quick, Siddhartha Mukherjee, Raul Rabadan, Martin P. Carroll, Azra Raza, Stavroula Kousteni

Blood (2021) 138 (Supplement 1): 4456.

https://doi.org/10.1182/blood-2021-147741

Published: 2021

Journal Articles

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Christian Hurtz, Gerald Wertheim, John Chukinas, Joseph Patrick Loftus, Sung June Lee, Anil Kumar, Rahul S. Bhansali, Srividya Swaminathan, Thierry Besson, Junwei Shi, John D. Crispino, Sarah K Tasian, Martin P. Carroll

Blood (2021) 138 (Supplement 1): 506.

https://doi.org/10.1182/blood-2021-144476

Published: 2021

Journal Articles

Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL

Asen Bagashev, Joseph Patrick Loftus, Colin Wakefield, Gerald Wertheim, Christian Hurtz, Martin P. Carroll, Kimberly Stegmaier, Yana Pikman, Sarah K Tasian

Blood (2021) 138 (Supplement 1): 705.

https://doi.org/10.1182/blood-2021-148671

Published: 2021

Journal Articles

Clonotype-Immunophenotype Relationships in TET2 and IDH -Mutant Myeloid Transformation

Linde A. Miles, Robert L. Bowman, Nicole Delgaudio, Troy Robinson, Martin P. Carroll, Sara E. Meyer, Ross L. Levine

Blood (2021) 138 (Supplement 1): 373.

https://doi.org/10.1182/blood-2021-151819

Published: 2021

Journal Articles

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

Caroline Duault, PharmD, PhD, Anil Kumar, PhD, Adeleh Taghi Khani, PhD, Sung June Lee, BA, Lu Yang, PhD, Min Huang, PhD, Christian Hurtz, PhD, Bryan Manning, BS, Lucy Ghoda, PhD, Tinisha McDonald, BS, Norman J. Lacayo, MD, Kathleen M. Sakamoto, MD PhD, Martin P. Carroll, MD, Guido Marcucci, MD, Jianhua Yu, PhD, Michael A. Caligiuri, MD, Holden T. Maecker, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-140044

Published: 2020

Journal Articles

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Christian Hurtz, PhD, Martin P. Carroll, MD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Rahul S. Bhansali, MDPhD, Sung June Lee, BA, Anil Kumar, PhD, Anne Lehman, Joseph Patrick Loftus, BS, Grace Jeschke, PhD, John D. Crispino, PhD, Thierry Besson, PhD, Junwei Shi, PhD, Srividya Swaminathan, PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-141258

Published: 2020

Journal Articles

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Shannon R. McCurdy, MD, Shannon H. Gier, BS, Daria V. Babushok, MD PhD, Noelle V. Frey, MD, Saar I. Gill, MD PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD MSCE, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Alexander E. Perl, MD, Ivan Maillard, MD PhD, Keith W. Pratz, MD, David L. Porter, MD, Martin P. Carroll, MD, Phyllis A. Gimotty, PhD, Selina M. Luger, MD FRCPC

Blood (2019) 134 (Supplement_1): 2209.

https://doi.org/10.1182/blood-2019-124468

Published: 2019

Journal Articles

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Linde A Miles, PhD, Robert L Bowman, PhD, Tiffany R Merlinsky, Aik Ooi, PhD, Pedro Mendez, Christopher Famulare, MS, Minal A Patel, MPH, Kelly Bolton, MD PhD, Neil Palmisiano, MD MS, Martin P. Carroll, MD, Elli Papaemmanuil, PhD, Ahmet Zehir, PhD, Sara E. Meyer, PhD, Aaron D Viny, MDMS, Ross L. Levine, MD

Blood (2019) 134 (Supplement_1): 913.

https://doi.org/10.1182/blood-2019-128763

Published: 2019

Journal Articles

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Zhigang Cai, PhD, Baskar Ramdas, PhD, Jonathan Kotzin, Martin P. Carroll, MD, Gerald Wertheim, MD, PhD, Adam Williams, Jorge Henao-Mejia, Reuben Kapur, PhD

Blood (2019) 134 (Supplement_1): 915.

https://doi.org/10.1182/blood-2019-130653

Published: 2019

Journal Articles

Bone Marrow Stromal Cells Protect Both FLT3-ITD and FLT3-WT Primary AML Cells from the Anti-Leukemic Activity of the FLT3 Inhibitor AC220

Cedric Dos Santos, PhD, Georges Habineza Ndikuyeze, Michael Nisssan, Chenghui Zhou, Xiaochuan Shan, MDPhD, Alexander E. Perl, MD, Martin P. Carroll, MD, Gwenn Danet-Desnoyers, PhD

Blood (2014) 124 (21): 4377.

https://doi.org/10.1182/blood.V124.21.4377.4377

Published: 2014

Journal Articles

Ultra-Deep Sequencing Defines Stem Cell-Specific Diversity Patterns in Acute Myelogenous Leukemia

Nuria Mencia-Trinchant, PhD, Gail J. Roboz, MD, Martin P. Carroll, MD, Monica L. Guzman, PhD, Duane C Hassane, PhD

Blood (2014) 124 (21): 4790.

https://doi.org/10.1182/blood.V124.21.4790.4790

Published: 2014

Journal Articles

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

Jingmei Hsu, MD PhD, Anita J. Kumar, MDMS, Martin P. Carroll, MD, Noelle V. Frey, MDMS, Nirav N. Shah, MD, Zhao Jianhua, PhD, Elizabeth O. Hexner, MD, Alison W. Loren, MD, James K. Mangan, MDPhD, Alexander E. Perl, MD, David Porter, MD, Jennifer Morrissette, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 2343.

https://doi.org/10.1182/blood.V124.21.2343.2343

Published: 2014

Journal Articles

A Measure of DNA Methylation for Predicting Outcome in De Novo AML

Marlise R. Luskin, MD, Phyllis A. Gimotty, PhD, Gerald Wertheim, MDPhD, Catherine Smith, Alison R. Sehgal, MD, Selina M. Luger, MD, Stephen R. Master, MDPhD, Alison W. Loren, MD, Martin P. Carroll, MD

Blood (2014) 124 (21): 2345.

https://doi.org/10.1182/blood.V124.21.2345.2345

Published: 2014

Journal Articles

Responsiveness of FLT3-ITD+ AML to Kinase Inhibition Correlates with High Allele Ratio and Relapsed Disease but Not to Inhibition of Canonical Targets

Mayumi Sugita, MD, Grace R Jeschke, Martin P. Carroll, MD, Alexander E. Perl, MD

Blood (2014) 124 (21): 2371.

https://doi.org/10.1182/blood.V124.21.2371.2371

Published: 2014

NARROW

The NSG-hIL6 Mouse As a Novel Murine Patient Derived Xenograft Model of Plasma Cell Dyscrasias for Study of Disease Biology and Therapeutic Development

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Real World Effectiveness of "7 + 3" Intensive Chemotherapy Vs Venetoclax and Hypomethylating Agent for Initial Therapy in Adult Acute Myeloid Leukemia

Targeting the Mevalonate Pathway in the Mitochondria-Dependent Chemotherapy Resistance of TP53 Mutant Acute Myeloid Leukemia

Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML

FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation

A Targetable Bone Marrow-Niche Axis for the Treatment of Acute Myeloid Leukemia

Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

Alisertib Synergistically Strengthens the Anti-Leukemia Activity of Venetoclax in TCF3-Hlf B-ALL

Clonotype-Immunophenotype Relationships in TET2 and IDH -Mutant Myeloid Transformation

Activated Natural Killer Cells Are Associated with Poor Clinical Prognosis in High-Risk B- and T- Cell Acute Lymphoblastic Leukemia

DYRK1A Is Required to Alleviate Replication Stress in KMT2A -Rearranged Acute Lymphoblastic Leukemia

Fried Frailty Phenotype Predicts Mortality for Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Single Cell DNA Sequencing Identifies Combinatorial Mutation Patterns and Clonal Architecture in Myeloid Malignancies

Lncrna Morrbid Regulates Myeloid Cell Survival of AML Driven By a Combination of FLT3ITD and Epigenetic Mutations

Bone Marrow Stromal Cells Protect Both FLT3-ITD and FLT3-WT Primary AML Cells from the Anti-Leukemic Activity of the FLT3 Inhibitor AC220

Ultra-Deep Sequencing Defines Stem Cell-Specific Diversity Patterns in Acute Myelogenous Leukemia

ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML?

A Measure of DNA Methylation for Predicting Outcome in De Novo AML

Responsiveness of FLT3-ITD+ AML to Kinase Inhibition Correlates with High Allele Ratio and Relapsed Disease but Not to Inhibition of Canonical Targets

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only